Kenji M Fujihara
Overview
Explore the profile of Kenji M Fujihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shin J, Mir H, Khurram M, Fujihara K, Dynlacht B, Cardozo T, et al.
Nat Metab
. 2023 Feb;
5(2):277-293.
PMID: 36747088
Metabolism is a fundamental cellular process that is coordinated with cell cycle progression. Despite this association, a mechanistic understanding of cell cycle phase-dependent metabolic pathway regulation remains elusive. Here we...
2.
Cabalag C, Prall O, Ciciulla J, Galea L, Thio N, Jayawardana M, et al.
Ann Surg Oncol
. 2022 Oct;
30(3):1614-1625.
PMID: 36183015
Background: In esophageal cancer (EC), there is a paucity of knowledge regarding the interplay between the tumor immune microenvironment and response to neoadjuvant treatment and, therefore, which factors may influence...
3.
Fujihara K, Zhang B, Jackson T, Ogunkola M, Nijagal B, Milne J, et al.
Sci Adv
. 2022 Sep;
8(37):eabm9427.
PMID: 36103522
The mechanism of action of eprenetapopt (APR-246, PRIMA-1) as an anticancer agent remains unresolved, although the clinical development of eprenetapopt focuses on its reported mechanism of action as a mutant-p53...
4.
Ceder S, Eriksson S, Liang Y, Cheteh E, Zhang S, Fujihara K, et al.
Cell Death Dis
. 2022 Aug;
13(8):672.
PMID: 35922423
No abstract available.
5.
Cabalag C, Yates M, Corrales M, Yeh P, Wong S, Zhang B, et al.
Ann Surg
. 2022 Jun;
276(2):e120-e126.
PMID: 35737908
Objective: To explore the clinical utility of circulating tumor DNA (ctDNA) in esophageal adenocarcinoma (EAC) by developing a cost-effective and rapid technique utilising targeted amplicon sequencing. Summary Of Background Data:...
6.
Jackson T, Crameri J, Muellner-Wong L, Frazier A, Palmer C, Formosa L, et al.
Proc Natl Acad Sci U S A
. 2022 Mar;
119(13):e2115566119.
PMID: 35333655
SignificanceMitochondria are double-membraned eukaryotic organelles that house the proteins required for generation of ATP, the energy currency of cells. ATP generation within mitochondria is performed by five multisubunit complexes (complexes...
7.
Fujihara K, Corrales Benitez M, Cabalag C, Zhang B, Ko H, Liu D, et al.
Mol Cancer Ther
. 2021 Jul;
20(10):1858-1867.
PMID: 34315763
APR-246 (eprenetapopt) is in clinical development with a focus on hematologic malignancies and is promoted as a mutant-p53 reactivation therapy. Currently, the detection of at least one mutation is an...
8.
Ceder S, Eriksson S, Liang Y, Cheteh E, Zhang S, Fujihara K, et al.
Cell Death Dis
. 2021 Jul;
12(7):709.
PMID: 34267184
Asparaginase depletes extracellular asparagine in the blood and is an important treatment for acute lymphoblastic leukemia (ALL) due to asparagine auxotrophy of ALL blasts. Unfortunately, resistance occurs and has been...
9.
Fujihara K, Zhang B, Clemons N
Antioxidants (Basel)
. 2021 Jul;
10(6).
PMID: 34205617
A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a...
10.
Gotovac J, Kader T, Milne J, Fujihara K, Lara-Gonzalez L, Gorringe K, et al.
Cell Mol Gastroenterol Hepatol
. 2021 Mar;
12(2):689-713.
PMID: 33774196
Background & Aims: Esophageal adenocarcinoma (EAC) develops from its precursor Barrett's esophagus through intermediate stages of low- and high-grade dysplasia. However, knowledge of genetic drivers and molecular mechanisms implicated in...